Multiple Myeloma | Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists – Part 6: Multiple Myeloma

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Noopur Raje and Saad Zafar Usmani, including the following topics: Introduction Front-Line Treatment for Transplant-Ineligible Patients; Incorporation of CAR T-Cell Therapy — Dr Choksi Up-Front Management of Multiple Myeloma in Young Patients with Adverse Cytogenetics Chalk Talk — Dr Raje Efficacy and Tolerability of Subcutaneous versus IV Daratumumab in Patients with Multiple Myeloma Chalk Talk — Dr Usmani (Part 1) Substitution of Isatuximab for Daratumumab; Role of Transplant; Role of Minimal Residual Disease — Dr Kumar Nonresearch Role of Venetoclax for Patients with R/R Multiple Myeloma and t(11;14) or Bcl-2 Overexpression Chalk Talk — Dr Usmani (Part 2) Case: A man in his mid-60s with relapsed/refractory multiple myeloma with t(4:14) and del(17p) — Dr Usmani Comment on Dr Usmani’s 64-Year-Old Man: High-Risk Cytogenetics — Paul G Richardson, MD and Peter Voorhees, MD Comment on Dr Usmani’s 64-Year-Old Man: CAR T-Cell Therapy — Drs Richardson and Voorhees CAR T-Cell Therapy Investigational Strategies Chalk Talk — Dr Raje Investigational Bispecific Antibodies for R/R Multiple Myeloma Chalk Talk — Dr Usmani CME information and select publications